Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Cullinan Therapeutics, Inc. (CGEM)

13.84 -0.14 (-1.00%)
At close: May 22 at 4:00:00 PM EDT
14.00 +0.16 (+1.16%)
Pre-Market: 7:22:06 AM EDT
Trade CGEM on Coinbase
Chart Range Bar
Loading chart for CGEM
  • Previous Close 13.98
  • Open 13.97
  • Bid 13.78 x 200
  • Ask 13.88 x 200
  • Day's Range 13.69 - 14.19
  • 52 Week Range 5.68 - 16.74
  • Volume 471,167
  • Avg. Volume 865,678
  • Market Cap (intraday) 850.579M
  • Beta (5Y Monthly) -0.09
  • PE Ratio (TTM) --
  • EPS (TTM) -3.37
  • Earnings Date (est.) Aug 6, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 31.45

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

cullinantherapeutics.com

109

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News: CGEM

View More
Cullinan Therapeutics: Q4 Earnings Snapshot

Cullinan Therapeutics: Q4 Earnings Snapshot

Performance Overview: CGEM

Trailing total returns as of 5/22/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CGEM
33.72%
S&P 500 (^GSPC)
9.17%

1-Year Return

CGEM
75.41%
S&P 500 (^GSPC)
27.93%

3-Year Return

CGEM
51.42%
S&P 500 (^GSPC)
78.25%

5-Year Return

CGEM
49.10%
S&P 500 (^GSPC)
79.83%

Earnings Trends: CGEM

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -49.66M

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-60M
-40M
-20M
0

Analyst Insights: CGEM

View More

Analyst Price Targets

23.00
31.45 Average
13.84 Current
38.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 5/19/2026
Analyst BTIG
Rating Action Reiterates
Rating Buy
Price Action Maintains
Price Target 38 -> 38

Statistics: CGEM

View More

Valuation Measures

Annual
As of 5/22/2026
  • Market Cap

    850.58M

  • Enterprise Value

    501.08M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    2.32

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -30.57%

  • Return on Equity (ttm)

    -48.16%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -221.04M

  • Diluted EPS (ttm)

    -3.37

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    351.88M

  • Total Debt/Equity (mrq)

    0.65%

  • Levered Free Cash Flow (ttm)

    -102.82M

Compare To: CGEM

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: CGEM

Fair Value

13.84 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports: CGEM

View More
  • Daily – Vickers Top Buyers & Sellers for 06/24/2022

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Daily – Vickers Top Buyers & Sellers for 05/17/2022

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Daily – Vickers Top Buyers & Sellers for 04/07/2022

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: